Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M173,514Revenue $M44,033Net Margin (%)12.9Z-Score3.1
Enterprise Value $M183,738EPS $1.5Operating Margin %14.4F-Score4
P/E(ttm))39.5Cash Flow Per Share $6.3Pre-tax Margin (%)15.5Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %3.1Quick Ratio1.6Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-6.3Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow7.1y-y EBITDA Growth Rate %-9.2ROA % (ttm)5.7Higher Current Ratio y-yN
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)11.6Less Shares Outstanding y-yY
Payout Ratio %92.0Shares Outstanding M2,922ROI % (ttm)6.0Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

MRK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MRK George Soros 2014-06-3086,80000.04New Buy
MRK Joel Greenblatt 2014-06-30126,84400.09+3456.04%
MRK Ruane Cunniff 2014-06-304,60900+4.54%
MRK James Barrow 2014-06-3022,793,2070.781.8+0.24%
MRK Mario Gabelli 2014-06-30160,3160.010.05
MRK Prem Watsa 2014-06-3012,00000.05
MRK Charles Brandes 2014-06-302,434,5310.081.7-0.68%
MRK Vanguard Health Care Fund 2014-06-3033,889,9481.165.2-4.85%
MRK Dodge & Cox 2014-06-3035,960,1371.232-10.01%
MRK Jean-Marie Eveillard 2014-06-301,755,0820.060.25-21.54%
MRK David Dreman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!

MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRAZIER KENNETH CChairman, President & CEO 2014-09-10Sell9,814$60.48-1.59view
Schechter Adam HEVP & Pres-Global Human Health 2014-08-25Sell22,000$59.7-0.3view
FRAZIER KENNETH CChairman, President & CEO 2014-08-11Sell10,058$574.42view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2014-08-04Sell28,669$56.645.08view
FRAZIER KENNETH CChairman, President & CEO 2014-07-10Sell9,987$58.032.57view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.160.61view
GRADDICK WEIR MIRIAN MExe V-P, HR 2014-07-07Sell180,047$59.160.61view
Deese Willie AExe V-P & Pres. MMD 2014-06-27Sell72,290$58.262.16view
FRAZIER KENNETH CChairman, President & CEO 2014-06-10Sell9,985$58.062.51view
Schechter Adam HEVP & Pres-Global Human Health 2014-05-14Sell10,527$55.916.46view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

    News about MRK:

    Articles On GuruFocus.com
    I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
    Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
    Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
    UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
    U.S. Markets Regain Losses from Last Week Jul 14 2014 
    Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
    U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 
    Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
    Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
    Wrong Marketing Lesson by Big Pharma May 03 2014 

    More From Other Websites
    Merck Serono to Broaden Its General Medicines Portfolio in Emerging Markets with Affordable,... Sep 16 2014
    AstraZeneca gets up to $500 million from Lilly for Alzheimer's drug Sep 16 2014
    Merck osteoporosis drug passes trial, but side effects hover Sep 15 2014
    Merck KGaA Stops All Tecemotide Studies for Lung Cancer Sep 15 2014
    Merck's Osteoporosis Drug Meets Primary Fracture Endpoints In Phase 3 Trial Sep 15 2014
    Merck says osteoporosis drug achieves goal in large trial Sep 15 2014
    1:31 pm Merck announces data from pivotal Phase 3 fracture outcomes study for odanacatib, an... Sep 15 2014
    Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational... Sep 15 2014
    Merck's Mantra On Focus Precludes An Inversion Strategy Sep 15 2014
    Stocks close down ahead of Fed meeting; energy hit Sep 12 2014
    Trading Guidelines for J&J, Merck, Pfizer, 8 Other Drug Companies Sep 12 2014
    Merck KGaA ends lung cancer vaccine trials Sep 12 2014
    Is Merck & Co., Inc. A Leader In A Red Hot Market? Sep 10 2014
    Dow Component Merck (MRK) To Go Ex-dividend Tomorrow Sep 10 2014
    TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant Sep 09 2014
    Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent Sep 08 2014
    Merck to Participate at the Morgan Stanley Global Healthcare Conference Sep 08 2014
    Bristol-Myers Sues Merck of Patent Infringement on Keytruda Sep 08 2014
    Bristol-Myers Sues Merck Over a Patent on its new Cancer Drug Sep 08 2014
    Bristol-Myers sues Merck over U.S. immunotherapy patent Sep 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial